A new generation of cancer-imaging nanoparticles could make it possible to detect tiny tumors deep inside the body without relying on continuous illumination from an external light source. Researchers have developed tumor-specific radioafterglow nanoprobes that use X-rays to generate a delayed near-infrared signal, then activate that signal in the presence of hydrogen peroxide, a chemically reactive molecule frequently elevated in the tumor microenvironment. The approach combines deep-tissue excitation, low background fluorescence and molecular specificity in a single imaging platform. In experiments described in Nature Protocols, the nanoprobes produced a signal-to-background ratio of 169 and enabled the detection and surgical removal of tumors as small as 1 cubic millimeter.
Conventional fluorescence imaging is powerful but faces a fundamental obstacle: biological tissues naturally emit light when illuminated. This autofluorescence can obscure weak signals from fluorescent probes, particularly when researchers attempt to identify very small lesions or image tissue several millimeters beneath the surface. Photoafterglow probes partly address this problem by storing optical energy and releasing it after the excitation light is switched off. Because the tissue is no longer being illuminated during image acquisition, the background can be substantially reduced. However, light used to charge these materials is strongly scattered and absorbed by tissue, limiting how deeply the probes can be activated.
Sonoafterglow systems replace optical excitation with ultrasound, but they also face limitations in reaching and energizing targets throughout the body. Radioafterglow nanoprobes take a different route by using X-rays as the external energy source. X-rays penetrate tissue much more effectively than visible or near-infrared light, allowing the imaging system to charge nanoparticles located deep inside the body. Once the irradiation ends, the particles continue to emit near-infrared light. This delayed emission eliminates the need for real-time excitation during image collection and can therefore suppress much of the tissue background that complicates conventional fluorescence imaging.
The reported radioafterglow nanoprobes are based on a cascade energy-conversion mechanism. Their formulation brings together three functional components: radioabsorbers, radiosensitizers and radioafterglow substrates. Radioabsorbers capture energy from X-rays, while radiosensitizers help convert that energy into a form that can excite the afterglow substrate. The substrate then releases the stored energy as near-infrared light. According to the researchers, the emission peaks at approximately 788 nanometers, a wavelength range that can travel through tissue more efficiently than visible light. The signal has an approximate half-life of 4.8 minutes, providing a practical window for imaging after the X-ray source has been turned off.
The particles are assembled inside amphiphilic polymers using a film rehydration method, a preparation strategy commonly used to package hydrophobic compounds into nanoscale carriers. In this process, the selected molecular components are first incorporated into a thin polymer film. Rehydration then causes the amphiphilic material to organize into nanosized structures that encapsulate the radioafterglow ingredients. The researchers describe the procedure as rapid, taking less than 10 minutes, while also offering control over the concentration of the compounds loaded into the nanoparticles. Because the method does not depend on elaborate layer-by-layer fabrication, it may be easier to scale than some more complex nanomaterial production techniques.
The latest design adds a molecular gate based on hydrogen peroxide. Tumors often contain higher levels of hydrogen peroxide because of altered metabolism, inflammation and oxidative stress. The molecule is not unique to cancer, and its concentration can vary among tissues and disease states, but it is an important marker of the biochemical conditions surrounding many tumors. In the new probes, hydrogen peroxide is used to activate or unmask the afterglow response. This means that the presence of the nanoparticles alone does not necessarily produce a strong signal; instead, the signal is designed to increase where the relevant chemical environment is present. Such activatable probes could help distinguish diseased tissue from surrounding healthy tissue more precisely than particles that emit continuously.
The performance reported for the system is particularly notable at the scale of small lesions. The researchers achieved a signal-to-background ratio of 169, indicating that the detected tumor-associated signal was far stronger than the surrounding background under the described experimental conditions. The probes also supported the imaging and surgical resection of tumors measuring approximately 1 cubic millimeter. That size is significant because early-stage lesions and microscopic residual disease can be difficult to locate during surgery. A probe that highlights small areas of tumor-associated chemistry could eventually complement anatomical imaging and help surgeons identify tissue that is not readily visible by eye.
The energy requirements may offer another advantage. The researchers report that the tumor-specific radioafterglow nanoprobes achieved their results using an X-ray dose 20 times lower than that required for inorganic materials used in comparable radioafterglow approaches. Lower radiation exposure is important for biomedical translation, although the acceptable dose depends on the imaging task, the distribution of the nanoparticles, the equipment and the regulatory setting. The claimed excitation depth reaches up to 15 centimeters, approximately three times deeper than reported for photoafterglow systems. This depth could make the technology relevant to targets located beneath the skin or within larger organs, where optical charging would be severely limited.
The protocol is intended to make the technology reproducible for researchers working across chemistry, biology and materials science. Nanoprobe construction and characterization typically require one to two weeks, followed by another one to two weeks of cell-based assays. Animal experiments are expected to take three to four weeks. These stages include evaluating particle formation and optical performance, testing hydrogen peroxide responsiveness in biological models, assessing cellular compatibility and determining whether the probes accumulate sufficiently in tumors. The workflow reflects the multidisciplinary nature of the platform: successful imaging depends not only on the chemistry of the afterglow materials, but also on nanoparticle delivery, tumor biology, X-ray exposure and image analysis.
Despite its striking results, the technology remains a research-stage platform rather than a clinically approved imaging method. Future studies will need to establish how the nanoparticles behave in humans, how long they remain in the body, how they are cleared, whether they trigger immune reactions and how reliably hydrogen peroxide levels distinguish tumors from inflamed or otherwise abnormal tissue. Researchers will also need to compare the approach with existing surgical imaging technologies and determine whether its deep-tissue sensitivity translates across different cancer types. Even with those questions unresolved, radioafterglow nanoprobes represent a significant conceptual advance: they use penetrating X-rays to charge a delayed near-infrared signal, then use tumor chemistry to decide where that signal appears. If the strategy survives further testing, it could provide surgeons and oncologists with a new way to see hidden cancer while keeping the imaging background exceptionally low.
Subject of Research: Tumor-specific radioafterglow nanoprobes for deep-tissue imaging of hydrogen peroxide and image-guided cancer surgery
Article Title: Synthesis of radioafterglow nanoprobes for deep-tissue imaging of hydrogen peroxide
Article References: Bai, S., Lin, Y., Xu, C. et al. Synthesis of radioafterglow nanoprobes for deep-tissue imaging of hydrogen peroxide. Nature Protocols (2026). https://doi.org/10.1038/s41596-026-01421-2
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41596-026-01421-2
Keywords: radioafterglow nanoprobes, deep-tissue imaging, hydrogen peroxide, cancer imaging, molecular imaging, X-ray excitation, near-infrared afterglow, image-guided surgery, tumor microenvironment, nanomedicine
Tags: advanced cancer surgical guidanceautofluorescence reduction techniquesdeep-tissue cancer imaginghydrogen peroxide detection in tumorslow-background fluorescence imagingmolecularly targeted nanoprobesnear-infrared signal activationRadioafterglow nanoprobessmall tumor detectiontumor microenvironment imagingtumor-specific nanoprobesX-ray induced imaging
